<DOC>
	<DOC>NCT01355016</DOC>
	<brief_summary>The purpose of this study is to determine the range of single inhaled doses of a new dry powder product, MDT-637, that are safe and well-tolerated. This includes monitoring effects on pulmonary function and determination of blood levels of MDT-637 following inhalation.</brief_summary>
	<brief_title>A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of MDT-637 in Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
	<criteria>Males and/or surgically sterile or postmenopausal females (confirmed by FSH test); males must agree to practice barrier contraception until they are discharged from the study Willing to give written informed consent 18 to 50 years of age BMI of 1930 Kg/m2 Nonsmoker (for at least 90 days prior to screening) and willing to abstain from smoking during the course of the study Good general health as determined by medical history, physical examination, ECG and clinical laboratory tests Willing to abstain from alcohol, caffeine, and xanthinecontaining beverages for 24 hours prior to and 24 hours after dosing Uncontrolled, clinically significant disease which in the opinion of the Principal Investigator and MDT would place the subject at risk through study participation or would confound the assessment of the safety of MDT637 Evidence of current or history of respiratory disease, including asthma, emphysema, chronic bronchitis, or cystic fibrosis History of significant nasal irritation from nasal inhalation of medication History of malignancy History of clinically significant alcohol or drug abuse Positive drug screen for drugs of abuse Positive test for HIV, Hepatitis B or Hepatitis C Allergy to lactose, or lactose intolerance Use of prescription medication within 14 days of Visit 2 or overthecounter preparations, including dietary and herbal supplements, within 5 days of Visit 2 Positive serum pregnancy test at Visit 1 Inability to perform reproducible spirometry Abnormal FEV1, FVC, or FEV1/FVC (FEV1and FVC &lt; 85% of predicted and variability of &lt;5% or FEV1/FVC ratio &lt; 0.7) Abnormal QTc interval at Visit 1(&gt;450 msec in males or &gt; 470 msec in females) Significant blood donation (or testing) in previous 8 weeks</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>RSV</keyword>
</DOC>